

Chiara Pighi received her master degree in Molecular Biotechnology and her PhD in Oncological Pathology from the University of Verona. She is currently a post-doctoral fellow in hematopathology in the Department of Biotechnology and Health Sciences of the University of Torino. During her PhD she worked on the molecular pathogenesis of mantle cell lymphoma and the identification of driver candidates of this process in the laboratory of Prof. Alberto Zamò and Prof. Aldo Scarpa (University of Verona). For her post-doc she joined the Molecular Oncology Laboratory of Prof. Roberto Chiarle at Boston Children's Hospital/Harvard Medical School in Boston, where she worked on the characterization of a novel tumor suppressor gene, FBXO11, in BCL6-positive lymphomas and the investigation of the genotoxic effects of PI3K $\delta$  target therapy in B cell malignancies.